



## Drug Formulary Update, October 2019 Medicare

Updates to the HealthPartners Medicare Formulary are listed below.

Please see [www.healthpartners.com/formularies](http://www.healthpartners.com/formularies) for details.

| Drug name                     | Current Status | New Status | Effective Date | Comments                                                          |
|-------------------------------|----------------|------------|----------------|-------------------------------------------------------------------|
| Amifampridine (Ruzurgi)       | NF             | T5 PA, NM  | 10/1/19        | A new FDA approval, added with coverage criteria.                 |
| Aripiprazole (Abilify Mycite) | NF             | T5 PA      | 8/31/19        | A recent FDA approval, added with coverage criteria.              |
| Bevacizumab (Mvasi)           | NF             | T5 PA      | 8/3/19         | A recently available biosimilar for Avastin, added with criteria. |
| Brexanolone (Zulresso)        | NF             | T5 PA      | 7/6/19         | A new FDA approval, added with coverage criteria.                 |
| Caplacizu (Cabliivi)          | NF             | T5 PA      | 8/1/19         | A new FDA approval, added with coverage criteria.                 |
| Darolutamide (Nubeqa)         | NF             | T5 PA      | 8/10/19        | A new FDA approval, added with coverage criteria.                 |
| Elapegade (Revcovi)           | NF             | T5 PA      | 8/1/19         | A recent FDA approval, added with coverage criteria.              |
| Entrectinib (Rozlytrek)       | NF             | T5 PA      | 8/31/19        | A new FDA approval, added with coverage criteria.                 |
| Esketamine (Spravato)         | NF             | T5 PA      | 6/8/19         | A new FDA approval, added with coverage criteria.                 |
| Fedratinib (Inrebic)          | NF             | T5 PA      | 8/31/19        | A new FDA approval, added with coverage criteria.                 |
| Insulin (Relion)              | NF             | T3         | 10/1/19        | Relion insulin has been added to formulary.                       |
| Levodopa (Inbrija)            | NF             | T5 PA      | 8/1/19         | A recent FDA approval, added with coverage criteria.              |
| Pexidartinib (Turalio)        | NF             | T5 PA      | 8/17/19        | A new FDA approval, added with coverage criteria.                 |

Formulary Abbreviations: T1 = Preferred Generic, T2 = Generic, T3 = Preferred Brand, T4 = Non-Preferred Drug, T5 = Specialty, NF = Non-Formulary, PA = Prior Authorization, QL = Quantity Limit, NM = Non-Mail Order, LA = Limited Access

| Drug name              | Current Status | New Status | Effective Date | Comments                                                          |
|------------------------|----------------|------------|----------------|-------------------------------------------------------------------|
| Polatuzumab (Polivy)   | NF             | T5 PA      | 6/22/19        | A new FDA approval, added with coverage criteria.                 |
| Risankizumab (Skyrizi) | NF             | T5 PA, NM  | 10/1/19        | A new FDA approval, added with coverage criteria.                 |
| Selinexor (Xpovio)     | NF             | T5 PA      | 7/20/19        | A new FDA approval, added with coverage criteria.                 |
| Trastuzumab (Kanjinti) | NF             | T5 PA      | 8/3/19         | A recently available biosimilar for Avastin, added with criteria. |

Formulary Abbreviations: T1 =Preferred Generic, T2 = Generic, T3 = Preferred Brand, T4 = Non-Preferred Drug, T5 = Specialty, NF = Non-Formulary, PA = Prior Authorization, QL = Quantity Limit, NM = Non-Mail Order, LA = Limited Access